NeoGenomics, Inc. — Q3 2012 Form 10-Q
Business context and reporting period. NeoGenomics operates high-complexity cancer diagnostic laboratories serving healthcare providers across the United States. This unaudited filing covers the quarter and nine months ended September 30, 2012; comparisons are with the corresponding 2011 periods unless noted. Financial amounts below are in millions of dollars unless stated otherwise.
Financial performance and position
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Revenue | $14.202 | $11.320 | $44.973 | $30.591 |
| Gross profit / margin | $5.892 / 41.5% | $5.074 / 44.8% | $20.402 / 45.4% | $13.595 / 44.4% |
| Operating income (loss) | $(0.684) | $0.042 | $1.015 | $(0.784) |
| Net income (loss) | $(0.975) | $(0.143) | $0.178 | $(1.329) |
| Adjusted EBITDA (non-GAAP) | $0.842 | $0.693 | $4.559 | $1.079 |
- Q3 requisitions rose 42.4% to 18,307 and tests performed rose 41.7% to 28,315. Nine-month requisitions increased 53.7% to 53,802 and tests increased 56.5% to 84,093.
- Average revenue per test fell 11.5% in Q3 to $501.58 and 6.1% for the nine months to $534.80. Q3 operating performance moved from modest operating income to loss; nine-month results returned to net income.
- At September 30, cash was $2.038 and restricted cash was $0.300. Accounts receivable was $12.013, compared with $7.894 at December 31, 2011. Working capital was $0.451; the current ratio was approximately 1.03.
- Nine-month operating cash flow was $(0.493), investing cash flow $(3.300), and financing cash flow $3.203. Cash declined $0.590 from year-end. The company attributed operating cash use mainly to receivables growth.
- Revolving-credit borrowings were approximately $8.0; the facility cap was $9.0 and reported availability approximately $0.3 after compensating cash. Equipment capital lease liabilities totaled $5.923, of which $2.513 was current. Total liabilities were $20.080.
Material changes and management commentary
- Revenue growth reflected added clients and expanded test offerings. Management reported that the Medicare Technical Component Grandfather clause expired effective July 1, 2012: the company must now bill hospitals for certain services previously billed to Medicare. This reduced average revenue per test and, management said, contributed to a $1.3 million revenue decline in Q3 versus Q2 2012. The affected services represented about 18% of the revenue base.
- Q3 gross margin declined 3.3 percentage points year over year, partly due to the reimbursement change. For the nine months, margin improved 1.0 point. Management cited lower cost per test from productivity, capacity planning, process improvements, fewer send-outs, and lower contract labor.
- Research and development expense rose to $0.808 in Q3 and $1.833 for the nine months, reflecting test development, personnel, stock compensation, and the HDC license. The January 2012 exclusive license covers specified cancer-testing and related technologies; the company committed to best efforts to commercialize initial products and faces potential loss of exclusivity for certain products if specified five-year revenue conditions are not met.
- Accounts receivable and collection timing were affected by new molecular billing codes adopted inconsistently by payers and by the shift from Medicare billing to hospital-client billing. Management expected Blue Cross Blue Shield Blue Card changes in Q4 2012 to add billing and collection complexity.
- Management said it believed available cash and credit resources were adequate for operating commitments, but noted additional borrowing or equity might be needed if operating cash flows do not fund growth. It anticipated $5.5–$6.5 million of additional capital equipment purchases over the next year, primarily financed through capital leases.
- Adjusted EBITDA is a company-defined non-GAAP measure; Q3 included $0.170 million of moving-related charges added back. The filing reports approximately $0.170 million of California-facility moving expenses, which management did not expect to recur.
Outlook, risks, and contingencies
- No specific revenue or earnings guidance is provided. Management expected modest sales and marketing expense growth with volume, while expecting those expenses and general and administrative expenses to decline as a percentage of revenue. It also expected continued cost-per-test improvement.
- Key disclosed risks include reimbursement and regulatory changes, payer billing and collection delays, bad debts, competition and customer internalization of testing, scaling facilities and systems, hiring and retaining personnel, and obtaining financing for growth and equipment.
- A single large oncology practice’s affiliated locations represented 12.9% of Q3 revenue and 15.4% of nine-month revenue, versus 13.5% and 8.8%, respectively, in the prior-year periods. No current legal proceedings were considered material. Management stated disclosure controls were effective at a reasonable assurance level, with no material quarterly change in internal control over financial reporting.
Investor facts to verify
- Whether reimbursement changes and payer adoption of billing codes continue to pressure revenue per test, margins, and collection times.
- Receivables aging, allowance adequacy, and operating cash flow conversion as revenue expands.
- Actual availability and terms under the credit facility, covenant compliance, and the capacity to finance planned capital expenditures.
- Progress and commercial revenue from HDC-licensed products, including the license’s commercialization milestones and exclusivity conditions.
- Revenue concentration in the large oncology practice and the sustainability of rapid test-volume growth.